Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid

Executive Summary

The pharma hopes showing a PFS benefit in first-line NSCLC patients with a high tumor mutation burden may provide a way to compete with Merck in that setting, but analysts think it will need overall survival data.


Related Content

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
Merck's Keytruda Keeps Nipping At Opdivo's Heels
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer
In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts